AbbVie announced the initiation of a global Phase 3 clinical trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). Veliparib is an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor being evaluated in multiple tumor types.
This placebo-controlled, double-blind, multicenter trial will evaluate patients (n=900) randomized to receive either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, vs. patients receiving carboplatin and paclitaxel with the addition of placebo. The primary efficacy outcome of the trial is overall survival (OS). Other pre-specified outcome measures include progression-free survival (PFS), and objective response rate (ORR). The safety of veliparib will also be evaluated in the trial.
Veliparib is currently being studied in more than a dozen cancers and tumor types, including breast, ovarian, and non-small cell lung cancers.
For more information call (800) 633-9110 or visit AbbVie.com.
This article originally appeared on MPR